Avid Bioservices Inc (CDMO)

[entdoc]

Iwfal, I missed some of this thread, so pardon the intrusion if it is off the mark. The number of disappointing results does not necessarily predict future results, and the spin-offs alone from being the development and production arm (PPHM) of a promising new technology is huge. Remember, Bavituximab began life as mouse-man chimera, a double-armed rocket, one arm capable of effecting docking with "flipped"membrane aminophospholipids, and the other capable of bearing a payload. The inventor (Thorpe) learned that unarmed, or naked Bavi had stronger attraction to cancer areas, and without a payload, alone, induced enhanced immune response by "turning on" macrophages (garbage collectors) that discourage cell division (ie. mitosis+cancer), and imprint a long-term body immune response to the tumor. Bavituximab is not going to reverse advanced solid tumors. It attacks them. Lights them up like a Christmas tree. But large solid tumors will still require combined therapy, surgery, chemo-, and irradiation. But that is the glory of Bavi. It does not compete at the table. It ENHANCES the response to traditional therapy. HOw much? How soon? Is the "marginal good" worth the price? If not, we have fully human Bavi awaiting a mission.